Last month, the WHO Strategic Advisory Group on Immunization published preliminary recommendations for the use of Moderna mRNA-1273 against COVID-19 in people over 18 years of age.
Now, Moderna Inc began dosing patients in the mid-final phase of its study of the COVID-19 mRNA-1273 vaccine in children aged six months to under 12 years, the company said Tuesday.
This study will evaluate the safety and efficacy of two doses of mRNA-1273 at 28-day intervals. And intends to include approximately 6,750 children in the US and Canada.
This vaccine now approved for use in an emergency in America aged 18 years and over.
In a separate study that began in December. Moderna also tested mRNA-1273 in adolescents between the ages of 12 and 18.
The latest study was conducted in collaboration with the National Institute for Allergies and Infectious Diseases (NIAID) and the Authority for Biomedical Research and Development (BARDA).
In the last Study who else can get Moderna vaccines?
This vaccine is safe and effective in people with diseases known to be associated with an increased risk of serious illnesses. Such as high blood pressure, diabetes, asthma, lung, liver, or kidney disease, and stable and controlled chronic infections.
Although further studies needed for people with weakened immune systems. People in this category who are part of the recommended group for vaccination can vaccinate after receiving information and advice.
People living with HIV are at a higher risk of getting severe COVID-19. Recipients of known HIV-positive vaccines should be informed and advised.
People who have COVID-19 can vaccinate. However, people may wish to postpone their own vaccination against COVID-19 for up to six months from when they became infected with SARS-CoV-2.
Vaccines can be given to breastfeeding women who are part of the recommended group for vaccination (eg health care workers). It is currently not recommended to stop breastfeeding after vaccination.